GSB Wealth Management LLC Has $1.31 Million Stock Position in Pfizer Inc. (NYSE:PFE)

GSB Wealth Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 14.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,780 shares of the biopharmaceutical company’s stock after selling 8,613 shares during the quarter. GSB Wealth Management LLC’s holdings in Pfizer were worth $1,312,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new stake in Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth about $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the 4th quarter valued at about $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $24.00 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a 50 day simple moving average of $23.14 and a 200 day simple moving average of $24.93. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm has a market capitalization of $136.47 billion, a PE ratio of 17.39, a P/E/G ratio of 0.89 and a beta of 0.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm earned $0.82 EPS. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.17%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.